Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 16/20 | 0.68 |
| ▸ | MMP3 | P08254 | 14/20 | 0.68 |
| ▸ | MMP13 | P45452 | 14/20 | 0.68 |
| ▸ | MMP9 | P14780 | 14/20 | 0.68 |
| ▸ | MMP1 | P03956 | 13/20 | 0.68 |
| ▸ | MMP7 | P09237 | 13/20 | 0.68 |
| ▸ | MMP14 | P50281 | 1/20 | 0.68 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.53 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7867746 | 1.00 | MMP2 (0.68) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL8283236 | 0.96 | MMP2 (0.61) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL3615326 | 0.96 | MMP2 (0.61) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL1656896 | 0.96 | MMP2 (0.61) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL7423321 | 0.90 | MMP9 (0.57) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL7935790 | 0.89 | MMP2 (0.69) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL8283343 | 0.89 | ADAMTS4 (0.67) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL1655654 | 0.89 | ADAMTS4 (0.67) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL3608270 | 0.88 | MMP2 (0.68) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL3608273 | 0.88 | MMP2 (0.68) | MMP2MMP3MMP13MMP9MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0901466-B1 | BIPHENYLSULFONAMIDE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2001-10-31 | — | — | EP | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| US-5756545-A | ANTIARTHRITIC AGENTS; OSTEOPOROSIS | WARNER-LAMBERT COMPANY (US) | 1998-05-26 | — | — | US | claimed |
| EP-0901466-B1 | BIPHENYLSULFONAMIDE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2001-10-31 | — | — | EP | disclosed |
| US-5756545-A | ANTIARTHRITIC AGENTS; OSTEOPOROSIS | WARNER-LAMBERT COMPANY (US) | 1998-05-26 | — | — | US | disclosed |